Tesaro Inc (TSRO)

142.01
3.60 2.60
NASDAQ : Health Care
Prev Close 138.44
Open 138.85
Day Low/High 138.03 / 142.72
52 Wk Low/High 29.51 / 94.01
Volume 753.05K
Avg Volume 1.05M
Exchange NASDAQ
Shares Outstanding 53.80M
Market Cap 7.38B
EPS -8.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced

Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced

Tesaro's newly approved PARP inhibitor Zejula is really 50% more expensive than its list price implies.

These Stocks Show a Change of Direction

These Stocks Show a Change of Direction

Finding bullish and bearish reversals in the market.

Biotech Premarket Movers: Cempra, Tesaro, Editas

Biotech Premarket Movers: Cempra, Tesaro, Editas

Cempra, Tesaro and Editas Medicine were among the biotech stock movers in premarket trading on Tuesday.

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

The new Tesaro ovarian cancer drug will be marketed under the brand name Zejula.

TESARO Announces U.S. FDA Approval Of ZEJULA™ (Niraparib) For Women With Recurrent Ovarian Cancer

TESARO Announces U.S. FDA Approval Of ZEJULA™ (Niraparib) For Women With Recurrent Ovarian Cancer

- ZEJULA is the first and only PARP inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancer

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca's PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo.

Incyte Pops on Continued Gilead Takeout Speculation

Incyte Pops on Continued Gilead Takeout Speculation

Shares were up 8% during intraday trading.

Invest Like a Venture Capitalist With These 4 Stocks

Invest Like a Venture Capitalist With These 4 Stocks

Here's a closer look at four of venture capital funds' favorite publicly traded names in 2017.

Forget the Snapchat IPO--Invest Like a Venture Capitalist With These 4 Stocks

Forget the Snapchat IPO--Invest Like a Venture Capitalist With These 4 Stocks

Venture capital funds added shares of these four publicly traded stocks to their portfolios last quarter. Should you?

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Clovis, Tesaro Soar on Astrazeneca Phase Three News

Clovis, Tesaro Soar on Astrazeneca Phase Three News

AstraZeneca shares, meanwhile, were less-than-moved by the news.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Morgan Stanley, Twitter, Tesaro: Doug Kass' Views

Morgan Stanley, Twitter, Tesaro: Doug Kass' Views

Doug Kass shares his thoughts on boosts to financials, and discusses what M&A speculation is doing to biotechs.

Analysts' Actions -- Ford, Intel, Twitter, Viacom and More

Analysts' Actions -- Ford, Intel, Twitter, Viacom and More

Here are Friday's top research calls, including an upgrade for Ford and downgrades for Intel, Twitter and Viacom.

Notable Wednesday Option Activity: TSRO, PRLB, SPSC

Notable Wednesday Option Activity: TSRO, PRLB, SPSC

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Tesaro Inc , where a total volume of 6,484 contracts has been traded thus far today, a contract volume which is representative of approximately 648,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 64% of TSRO's average daily trading volume over the past month, of 1.0 million shares.

Biotech Tesaro Climbs on Takeout Reports

Biotech Tesaro Climbs on Takeout Reports

The company's shares were up 14% on rumors that it is working with investment banks to consider a sale.